In vivo characterization of a prostate-specific antigen promoter-based suicide gene therapy for the treatment of benign prostatic hyperplasia

Gene Therapy

Volumn 10, Issue 13, 2003, Pages 1129-1134

  Park, H S ^a,b   Cheon, J ^a,b   Cho, H Y ^b,c   Ko, Y H ^a   Bae, J H ^a   Moon, D G ^a,b   Kim, J J ^a  

^a Korea University College of Medicine   (South Korea)

^b Korea University   (South Korea)

^c Gachon University College of Medicine   (South Korea)

Author keywords

Prostate specific antigen; Prostatic hyperplasia

Indexed keywords

ACICLOVIR; ADENOVIRUS VECTOR; PROSTATE SPECIFIC ANTIGEN; THYMIDINE KINASE; ANTIVIRUS AGENT;

ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; CELL COUNT; CONTROLLED STUDY; DOG; DRUG EFFICACY; GENE TARGETING; HERPES SIMPLEX VIRUS; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; LAPAROTOMY; LYMPHOCYTIC INFILTRATION; MALE; NICK END LABELING; NONHUMAN; PLASMA CELL; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE HYPERTROPHY; SUICIDE GENE THERAPY; TRANSCRIPTION REGULATION; VIRAL GENE DELIVERY SYSTEM; VIRUS RECOMBINANT; ADENOCARCINOMA; ANIMAL; ENZYMOLOGY; EPITHELIUM CELL; GENE THERAPY; GENETICS; IMMUNOLOGY; INTRALESIONAL DRUG ADMINISTRATION; METHODOLOGY; PROSTATE TUMOR;

ADENOVIRIDAE; ANIMALIA; CANIS FAMILIARIS; SIMPLEXVIRUS;

ACYCLOVIR; ADENOCARCINOMA; ANIMALS; ANTIVIRAL AGENTS; APOPTOSIS; DOGS; EPITHELIAL CELLS; GENE THERAPY; IMMUNOHISTOCHEMISTRY; IN SITU NICK-END LABELING; INJECTIONS, INTRALESIONAL; MALE; PROMOTER REGIONS (GENETICS); PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; SIMPLEXVIRUS; THYMIDINE KINASE;

EID: 0038601428     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3301972     Document Type: Article

References (30)

1. Parker SH, Tong T, Bolden S, Wingo PA. Cancer statistics 1996. CA Cancer J Clin 1996; 46: 5-27.
2. Saginer PP et al. Results of an epidemiological survey using a modified American Urological Association Symptom Index for benign prostatic hyperplasia in France. J Urol 1994; 151: 1266-1270
3. Chute CG et al. The prevalence of prostatism: a population-based survey of urinary symptoms. J Urol 1993; 150: 85-89.
4. Stamey TA, Kabalin JN. Prostatic specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. I. Untreated patients. J Urol 1989; 141: 1070-1075.
5. Latham JP, Searle PF, Mautner V, James ND. Prostate-specific antigen promoter/enhancer driven gene therapy for prostatic cancer: construction and testing of tissue-specific adenovirus vector. Cancer Res 2000; 60: 334-341.
6. Martiniello-Wilks R et al. In vivo gene therapy for prostate cancer: preclinical evaluation of two different enzyme-directed prodrug therapy system delivered by identical adenovirus vectors. Hum Gene Ther 1998; 9: 1617-1626.
7. Moolten FL. Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy. Cancer Res 1986; 46: 5276-5281.
8. Moolten FL, Wells JM. Curability of tumors bearing herpes simplex thymidine kinase gene transferred by retroviral vectors. J Natl Cancer Inst 1990; 84: 297-300.
9. Shalev M et al. Suicide gene therapy for prostate cancer using a replication-deficient adenovirus containing the herpes virus-thymidine kinase gene. World J Urol 2000; 18: 125-129.
10. Shalev M et al. Suicide gene therapy toxicity after multiple and repeat in patients with localized prostate cancer. J Urol 2000; 163: 1747-1750.
11. Feng M et al. Neoplastic reversion accomplished by high efficiency adenoviral-mediated delivery of an anti-ras ribozyme. Cancer Res 1995; 55: 2024-2028.
12. Graham FL, Prevec L. Methods for construction of adenovirus vectors. Mol Biotechnol 1995; 3: 207-220.
13. Xu HJ et al. Enhanced tumor suppressor gene therapy via replication-deficient adenovirus vectors expressing an N-terminal truncated retinoblastoma protein. Cancer Res 1996; 56: 2245-2249.
14. Rocco JW et al. P16/INK4A adenovirus-mediated gene therapy for human head and neck squamous cancer cell. Clin Cancer Res 1998; 4: 1697-1704.
15. Lowseth LA, Gerlach RF, Gillett NA, Muggenburg BA. Age-related changes in the prostate and testes of the beagle dog. Vet Pathol 1990; 27: 347-353.
16. Steiner MS, Zhang Y, Carraher J, Lu Y. In vivo expression of prostate-specific adenovirus vectors in a canine model. Cancer Gene Ther 1999; 6: 456-464.
17. Vile RG, Hart IR. In vitro and in vivo targeting of gene expression to melanoma cells. Cancer Res 1993; 53: 962-967.
18. Macri P, Gordon JW. Delayed morbidity and mortality of albumin/SV 40 T-antigen transgenic mice after insertion of an alpha-fetoprotein/herpes virus thymidine kinase transgene and treatment with gancyclovir. Hum Gene Ther 1994; 5: 175-182.
19. Lu Y et al. Delivery of adenoviral vectors to the prostate for gene therapy. Cancer Gene Ther 199; 6: 64-72.
20. Lu Y, Steiner MS. Transcriptionally regulated adenoviruses for prostate-specific gene therapy. World J Urol 2000; 18: 93-101.
21. Watt KW et al. Human prostate-specific antigen: structure and functional similarity with serine proteases. Proc Natl Acad Sci USA 1986; 83: 3166-3170.
22. McEntee M, Isaacs W, Smith C. Adenocarcinoma of canine prostate: immunohistochemical examination for secretory antigens. Prostate 1987; 11: 163-170.
23. Pang S et al. Prostate tissue specificity of the prostate-specific antigen promoter isolated from a patient with prostate cancer. Hum Gene Ther 1995; 6: 1417-1426.
24. Gotoh A et al. Deveolpment of prostate-specific antigen promoter-based gene therapy for androgen-independent human prostate cancer. J Urol 1998; 160: 220-229.
25. Elshami AA et al. Gap junctions play a role in the 'bystander effect' of the herpes simplex virus thymidine kinase/gancyclovir sytem in vitro. Gene Therapy 1996; 3: 85-92.
26. Bi WL, Parysek LM, Warnick R, Stambrrok PL. In vitro evidence that metabolic cooperation is responsible for the bystander effect observed with HSV-TK retroviral gene therapy. Hum Gene Ther 1993; 4: 725-731.
27. Perez-Cruet MJ et al. Adenovirus-mediated gene therapy of experimental gliomas. J Neurosci 1994; 39: 506-511.
28. Herman JR et al. In situ gene therapy for adenocarcinoma of the prostate a phase I clinical trial. Hum Gene Ther 1999; 10: 1239-1249.
29. Park JY et al. Retinoids augment the bystander effect in vitro and in vivo in herpes simplex virus thymidine kinase/gancyclovir mediated gene therapy. Gene Therapy 1997; 4: 909-917.
30. Touraine RL et al. Enhancement of the herpes simplex virus thymidine kinase/gancyclovir bystander effect and its antitumor efficacy in vivo by pharmacologic manipulation of gap junctions. Hum Gene Ther 1998; 9: 2385-2391.